The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Cytokine inhibition in the treatment of COPD
Open accessAbstract
Cytokines play an important part in many pathobiological processes of chronic obstructive pulmonary disease (COPD), including the chronic inflammatory process, emphysema, and altered innate immune response. Proinflammatory cytokines of potential importance include tumor necrosis factor (TNF)-α, interferon-γ, interleukin (IL)-1β, IL-6, IL-17, IL-18, IL-32, and thymic stromal lymphopoietin (TSLP), and growth factors such as transforming growth factor-β. The current objectives of COPD treatment are to reduce symptoms, and to prevent and reduce the number of exacerbations. While current treatments achieve these goals to a certain extent, preventing the decline in lung function is not currently achievable. In addition, reversal of corticosteroid insensitivity and control of the fibrotic process while reducing the emphysematous process could also be controlled by specific cytokines. The abnormal pathobiological process of COPD may contribute to these fundamental characteristics of COPD, and therefore targeting cytokines involved may be a fruitful endeavor. Although there has been much work that has implicated various cytokines as potentially playing an important role in COPD, there have been very few studies that have examined the effect of specific cytokine blockade in COPD. The two largest studies that have been reported in the literature involve the use of blocking antibody to TNFα and CXCL8 (IL-8), and neither has provided benefit. Blocking the actions of CXCL8 through its CXCR2 receptor blockade was not successful either. Studies of antibodies against IL-17, IL-18, IL-1β, and TSLP are currently either being undertaken or planned. There is a need to carefully phenotype COPD and discover good biomarkers of drug efficacy for each specific target. Specific groups of COPD patients should be targeted with specific anticytokine therapy if there is evidence of high expression of that cytokine and there are features of the clinical expression of COPD that will respond.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330
Characterisation of COPD heterogeneity in the ECLIPSE cohort
the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators, Agusti, A., Calverley, P. M., Celli, B., Coxson, H. O., Edwards, L. D., Lomas, D. A., MacNee, W., Miller, B. E., Rennard, S., et al. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-122 · Cited by 1,157
Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations
Papi, A., Bellettato, C. M., Braccioni, F., Romagnoli, M., Casolari, P., Caramori, G., Fabbri, L. M., & Johnston, S. L. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200506-859oc · Cited by 1,072
Self-citationCarriere, V., Roussel, L., Ortega, N., Lacorre, D.-A., Americh, L., Aguilar, L., Bouche, G., & Girard, J.-P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606854104 · Cited by 966
Chen, C.-J., Kono, H., Golenbock, D., Reed, G., Akira, S., & Rock, K. L. (2007) · Nature Medicine · doi:10.1038/nm1603 · Cited by 876
Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights
Adcock, I. M., Caramori, G., & Barnes, P. J. (2011) · Respiration · doi:10.1159/000324601 · Cited by 257
Self-citationSCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects
Holz, O., Khalilieh, S., Ludwig-Sengpiel, A., Watz, H., Stryszak, P., Soni, P., Tsai, M., Sadeh, J., & Magnussen, H. (2010) · European Respiratory Journal · doi:10.1183/09031936.00048509 · Cited by 183
Skeletal Muscle Inflammation and Nitric Oxide in Patients with COPD
Montes de Oca, M., Torres, S. H., De Sanctis, J., Mata, A., Hernández, N., & Tálamo, C. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00107404 · Cited by 123
TNFα Antagonists for Acute Exacerbations of COPD: A Randomised Double-Blind Controlled Trial
Aaron, S. D., Vandemheen, K. L., Maltais, F., Field, S. K., Sin, D. D., Bourbeau, J., Marciniuk, D. D., FitzGerald, J. M., Nair, P., & Mallick, R. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202432 · Cited by 103
Elevated Levels of IL-18 in Plasma and Skeletal Muscle in Chronic Obstructive Pulmonary Disease
Petersen, A. M. W., Penkowa, M., Iversen, M., Frydelund-Larsen, L., Andersen, J. L., Mortensen, J., Lange, P., & Pedersen, B. K. (2007) · Lung · doi:10.1007/s00408-007-9000-7 · Cited by 83
Cited by
In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
Lizotte, P. H., Wen, A. M., Sheen, M. R., Fields, J., Rojanasopondist, P., Steinmetz, N. F., & Fiering, S. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.292 · Cited by 485
Association of clonal hematopoiesis with chronic obstructive pulmonary disease
Miller, P. G., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., et al. (2022) · Blood · doi:10.1182/blood.2021013531 · Cited by 235
Metadata
- Authors
- Chung, K. F., Caramori, G., Adcock, I., & Di Stefano, A.
- Venue
- International Journal of Chronic Obstructive Pulmonary Disease
- Publisher
- Informa UK Limited
- Published
- 2014-04
- Volume
- 9
- Pages
- 397
- ISSN
- 1176-9106 (ISSN-L)
- 1178-2005
- OpenAlex
- W1976310141
- Cited by
- 163
- References
- 10
- FWCI
- 15.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cytokine inhibition in the treatment of COPD. https://app.cochat.ai/papers/10.2147/copd.s42544
- The paper
- Chung, K. F., Caramori, G., Adcock, I., & Di Stefano, A. (2014). Cytokine inhibition in the treatment of COPD. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s42544
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.